Also from this source


22 Jun, 2017, 15:52 ET AbbVie Declares Quarterly Dividend

You just read:

AbbVie Announces Ibrutinib (IMBRUVICA®) Supplemental New Drug Application for Previously Treated Chronic Graft-Versus-Host-Disease (cGVHD) Accepted for Review by U.S. FDA

News provided by

AbbVie

04 Apr, 2017, 07:00 ET